4574 — Taiko Pharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00- ¥14bn
- ¥11bn
- ¥6bn
- 55
- 33
- 12
- 22
Annual income statement for Taiko Pharmaceutical Co, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2020 March 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 14,966 | 11,299 | 5,040 | 6,120 | 6,292 |
| Cost of Revenue | |||||
| Gross Profit | 10,608 | 3,326 | 1,079 | 2,577 | 3,666 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 11,270 | 20,125 | 9,961 | 10,028 | 5,796 |
| Operating Profit | 3,696 | -8,826 | -4,921 | -3,908 | 496 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 3,504 | -8,887 | -4,869 | -3,563 | 565 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 2,453 | -9,593 | -4,894 | -3,610 | 897 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 2,453 | -9,593 | -4,894 | -3,610 | 897 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 2,453 | -9,594 | -4,895 | -3,611 | 898 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 59.4 | -163 | -84.8 | -37.4 | 19.6 |
| Dividends per Share | |||||
| Special Dividends per Share |